Calluna Pharma has successfully completed enrollment for its global Phase 2 AURORA study of CAL101, a monoclonal antibody targeting the damage-associated protein S100A4, in patients with idiopathic pulmonary fibrosis (IPF). The study enrolled 161 adult patients across over 50 sites in the US, UK, EU, Turkey, and South Korea, utilizing a randomized, double-blind, placebo-controlled design with a 3:2 randomization ratio. Following a 28-day screening period, participants will receive monthly intravenous infusions of CAL101 or placebo for six months, with the primary endpoint focusing on the change in forced vital capacity from baseline. Notably, enrollment concluded more than six months ahead of schedule, with topline data anticipated in the first quarter of 2027.

The significance of this trial lies in its potential to address a critical unmet need in IPF, a condition characterized by a median survival of just 3 to 5 years and affecting approximately 233,000 individuals in the US and EU. CAL101’s mechanism of action, targeting S100A4, suggests a novel therapeutic approach to preserving lung function in patients suffering from this debilitating disease. Previous Phase 1 studies have indicated a favorable safety profile and predictable pharmacokinetics, while preclinical data support its efficacy in both preventing and treating fibrosis, which is central to IPF pathology.

The implications of this study extend to the broader landscape of fibrotic disease research and therapeutic development. If successful, CAL101 could shift current paradigms regarding IPF treatment strategies, potentially leading to new avenues for drug development that prioritize targeted therapies against specific molecular pathways involved in fibrosis. This may also accelerate the timeline for future clinical trials aimed at similar mechanisms, enhancing the prospects for effective interventions in fibrotic diseases.

Source: longevity.technology